HC Wainwright Reaffirms Neutral Rating for Bolt Biotherapeutics (NASDAQ:BOLT)

HC Wainwright restated their neutral rating on shares of Bolt Biotherapeutics (NASDAQ:BOLT) in a research report released on Wednesday morning,Benzinga reports. HC Wainwright also issued estimates for Bolt Biotherapeutics’ Q4 2024 earnings at ($0.34) EPS, FY2024 earnings at ($1.57) EPS, FY2025 earnings at ($0.94) EPS and FY2026 earnings at ($0.74) EPS.

Bolt Biotherapeutics Stock Down 9.1 %

Shares of NASDAQ BOLT opened at $0.57 on Wednesday. The company has a quick ratio of 4.28, a current ratio of 3.16 and a debt-to-equity ratio of 0.21. The business’s 50 day moving average is $0.64 and its two-hundred day moving average is $0.73. Bolt Biotherapeutics has a 52-week low of $0.55 and a 52-week high of $1.56. The firm has a market cap of $21.64 million, a price-to-earnings ratio of -0.33 and a beta of 0.92.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.04). Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The firm had revenue of $1.14 million during the quarter, compared to analysts’ expectations of $1.02 million. Research analysts predict that Bolt Biotherapeutics will post -1.52 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Assenagon Asset Management S.A. purchased a new position in Bolt Biotherapeutics in the 2nd quarter valued at approximately $26,000. Acuitas Investments LLC raised its stake in shares of Bolt Biotherapeutics by 21.7% in the second quarter. Acuitas Investments LLC now owns 630,507 shares of the company’s stock valued at $473,000 after acquiring an additional 112,555 shares in the last quarter. Finally, FMR LLC boosted its holdings in Bolt Biotherapeutics by 33.2% in the third quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after purchasing an additional 28,773 shares during the period. Institutional investors and hedge funds own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.